SCHEMBL30929009

SCHEMBL30929009

Cc1cccc(C(=O)OC(=O)O)c1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.50
MEN1 O00255 2/20 0.50
HSD17B10 Q99714 3/20 0.46
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 2/20 0.46
HPGD P15428 2/20 0.46
TDP1 Q9NUW8 2/20 0.45
CYP3A4 P08684 2/20 0.45
CYP2C9 P11712 2/20 0.45
LMNA P02545 2/20 0.45
TRPA1 O75762 2/20 0.45
AKR1B10 O60218 1/20 0.45
ABCB11 O95342 1/20 0.45
DHFR P00374 1/20 0.45
MPO P05164 1/20 0.45
CYP1A2 P05177 1/20 0.45
CHRM1 P11229 1/20 0.45
AKR1B1 P15121 1/20 0.45
PTGS1 P23219 1/20 0.45
PTGS2 P35354 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32667968 0.90 MEN1 (0.50) KMT2AMEN1HSD17B10KDM4EALDH1A1
SCHEMBL6113326 0.90 MEN1 (0.50) KMT2AMEN1HSD17B10KDM4EALDH1A1
SCHEMBL30426368 0.85 HSD17B10 (0.47) KMT2AMEN1HSD17B10KDM4EALDH1A1
SCHEMBL7893551 0.85 HSD17B10 (0.47) KMT2AMEN1HSD17B10KDM4EALDH1A1
SCHEMBL27492484 0.85 TSHR (0.47) KMT2AMEN1HSD17B10KDM4EALDH1A1
SCHEMBL6113332 0.84 KMT2A (0.50) KMT2AMEN1HSD17B10KDM4EALDH1A1
SCHEMBL2784301 0.83 KMT2A (0.46) KMT2AMEN1HSD17B10KDM4EALDH1A1
SCHEMBL126498 0.82 MEN1 (0.50) KMT2AMEN1HSD17B10KDM4EALDH1A1
SCHEMBL27424201 0.81 KMT2A (0.45) KMT2AMEN1HSD17B10KDM4EALDH1A1
SCHEMBL22639009 0.80 KMT2A (0.47) KMT2AMEN1HSD17B10KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12415787-B2 Process for the production of tetraaminobiphenol macrocyclic ligands; and novel tetraaminobiphenol macrocyclic ligands ECONIC TECHNOLOGIES LTD. (GB) 2025-09-16 US disclosed
US-20240182432-A1 PROCESS FOR THE PRODUCTION OF TETRAAMINOBIPHENOL MACROCYCLIC LIGANDS; AND NOVEL TETRAAMINOBIPHENOL MACROCYCLIC LIGANDS ECONIC TECHNOLOGIES LTD. (GB) 2024-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12415787-B2 Process for the production of tetraaminobiphenol macrocyclic ligands; and novel tetraaminobiphenol macrocyclic ligands MRPL21, MYCBP, TTL KMT2A 1511/4885MEN1 1931/4885HSD17B10 4239/4885
US-20240182432-A1 PROCESS FOR THE PRODUCTION OF TETRAAMINOBIPHENOL MACROCYCLIC LIGANDS; AND NOVEL TETRAAMINOBIPHENOL MACROCYCLIC LIGANDS MRPL21, MYCBP, TTL KMT2A 1511/4885MEN1 1931/4885HSD17B10 4239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.